(VIANEWS) - Falcon Minerals Corporation (FLMN), Century Casinos (CNTY), iRadimed Corporation (IRMD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Falcon Minerals Corporation (FLMN)
45.6% sales growth and 7.64% return on equity
Falcon Minerals Corporation owns royalty and mineral interests in North American oil and gas properties.
Falcon Minerals Corporation's sales growth this year is expected to be 68.6% and 14.7% for next year.
Year-on-year quarterly revenue growth grew by 103.6%, now sitting on 63.62M for the twelve trailing months.
Volume
Today's last reported volume for Falcon Minerals Corporation is 339910 which is 63.21% below its average volume of 924027.
Falcon Minerals Corporation's sales growth for the next quarter is 45.6%. The company's growth estimates for the ongoing quarter and the next is 700% and 400%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.64%.
Volatility
Falcon Minerals Corporation's last day, last week, and last month's current intraday variation average was 0.14%, 1.11%, and 1.88%, respectively.
Falcon Minerals Corporation's highest amplitude of average volatility was 3.62% (day), 3.07% (last week), and 4.59% (last month), respectively.
Falcon Minerals Corporation's Stock Yearly Top and Bottom Value
Falcon Minerals Corporation's stock is valued at $7.31 at 11:22 EST, below its 52-week high of $7.32 and way higher than its 52-week low of $4.24.
Falcon Minerals Corporation's Moving Average
Falcon Minerals Corporation's worth is way higher than its 50-day moving average of $5.95 and way higher than its 200-day moving average of $5.24.2. Century Casinos (CNTY)
34.9% sales growth and 15.7% return on equity
Century Casinos, Inc. is a global casino entertainment company.
Century Casinos's sales growth this year is anticipated to be 14.8% and 19.6% for next year.
Year-on-year quarterly revenue growth grew by 26.5%, now sitting on 388.51M for the twelve trailing months.
Volume
Today's last reported volume for Century Casinos is 54726 which is 57.72% below its average volume of 129441.
Century Casinos's sales growth for the next quarter is 34.9%. The company's growth estimates for the current quarter and the next is 360% and 18.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.7%.
Volatility
Century Casinos's last day, last week, and last month's current intraday variation average was 1.26%, 2.57%, and 4.26%, respectively.
Century Casinos's highest amplitude of average volatility was 2.53% (day), 3.90% (last week), and 6.59% (last month), respectively.
Century Casinos's Stock Yearly Top and Bottom Value
Century Casinos's stock is valued at $12.10 at 11:22 EST, way under its 52-week high of $16.44 and way higher than its 52-week low of $8.82.
Century Casinos's Moving Average
Century Casinos's worth is above its 50-day moving average of $11.25 and below its 200-day moving average of $12.76.3. iRadimed Corporation (IRMD)
20% sales growth and 13.97% return on equity
IRADIMED CORPORATION designs, produces, markets and distributes compatible magnetic resonance imaging (MRI), medical devices and accessories in the United States as well as internationally.
iRadimed Corporation's sales growth this year is anticipated to be 31.1% and 9.7% for next year.
Year-on-year quarterly revenue growth grew by 38.9%, now sitting on 41.81M for the twelve trailing months.
Volume
Today's last reported volume for iRadimed Corporation is 43050 which is 56.24% below its average volume of 98393.
iRadimed Corporation's sales growth for the next quarter is 20%. The company's growth estimates for the present quarter and the next is 200% and 115.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.97%.
Volatility
iRadimed Corporation's last day, last week, and last month's current intraday variation average was 2.12%, 5.09%, and 3.44%, respectively.
iRadimed Corporation's highest amplitude of average volatility was 3.54% (day), 10.30% (last week), and 7.32% (last month), respectively.
iRadimed Corporation's Stock Yearly Top and Bottom Value
iRadimed Corporation's stock is valued at $45.79 at 11:22 EST, way below its 52-week high of $55.92 and way higher than its 52-week low of $23.63.
iRadimed Corporation's Moving Average
iRadimed Corporation's value is below its 50-day moving average of $46.61 and way above its 200-day moving average of $39.64.4. Antares Pharma (ATRS)
17.4% sales growth and 63.08% return on equity
Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing pharmaceutical products and technologies to address unmet medical needs.
Antares Pharma's sales growth this year is expected to be 22.1% and 23.2% for next year.
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 179.38M for the twelve trailing months.
Volume
Today's last reported volume for Antares Pharma is 899593 which is 14.4% above its average volume of 786311.
Antares Pharma's sales growth for the next quarter is 17.4%. The company's growth estimates for the present quarter and the next is a negative 66.7% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 63.08%.
Volatility
Antares Pharma's last day, last week, and last month's current intraday variation average was 0.74%, 0.79%, and 1.53%, respectively.
Antares Pharma's highest amplitude of average volatility was 2.48% (day), 2.87% (last week), and 3.34% (last month), respectively.
Antares Pharma's Stock Yearly Top and Bottom Value
Antares Pharma's stock is valued at $4.10 at 11:22 EST, way under its 52-week high of $4.63 and way above its 52-week low of $3.11.
Antares Pharma's Moving Average
Antares Pharma's value is way above its 50-day moving average of $3.66 and higher than its 200-day moving average of $3.75.5. Veeco Instruments (VECO)
10.6% sales growth and 6.16% return on equity
Veeco Instruments Inc. and its affiliates develop, manufacture, sell, support and maintain semiconductor and thin-film process equipment used primarily for electronic devices around the world.
Veeco Instruments's sales growth this year is anticipated to be 13.6% and 12.3% for next year.
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 583.28M for the twelve trailing months.
Volume
Today's last reported volume for Veeco Instruments is 383047 which is 20.93% below its average volume of 484498.
Veeco Instruments's sales growth for the next quarter is 10.6%. The company's growth estimates for the current quarter and the next is 40% and 8.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.
Volatility
Veeco Instruments's last day, last week, and last month's current intraday variation average was 2.66%, 2.90%, and 2.20%, respectively.
Veeco Instruments's highest amplitude of average volatility was 4.13% (day), 4.42% (last week), and 3.65% (last month), respectively.
Veeco Instruments's Stock Yearly Top and Bottom Value
Veeco Instruments's stock is valued at $26.27 at 11:22 EST, way below its 52-week high of $32.40 and way higher than its 52-week low of $20.13.
Veeco Instruments's Moving Average
Veeco Instruments's value is below its 50-day moving average of $27.75 and above its 200-day moving average of $25.25.6. AbbVie (ABBV)
7.8% sales growth and 86.59% return on equity
AbbVie Inc. develops, produces, and markets pharmaceuticals across the United States, Japan and Canada.
AbbVie's sales growth this year is expected to be 22.8% and 6.4% for next year.
Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 56.2B for the twelve trailing months.
Volume
Today's last reported volume for AbbVie is 2912670 which is 62.88% below its average volume of 7848510.
AbbVie's sales growth for the next quarter is 7.8%. The company's growth estimates for the ongoing quarter and the next is 12.3% and 9.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 86.59%.
Volatility
AbbVie's last day, last week, and last month's current intraday variation average was 0.07%, 0.75%, and 0.84%, respectively.
AbbVie's highest amplitude of average volatility was 0.95% (day), 1.61% (last week), and 1.97% (last month), respectively.
AbbVie's Stock Yearly Top and Bottom Value
AbbVie's stock is valued at $168.67 at 11:22 EST, higher than its 52-week high of $164.66.
AbbVie's Moving Average
AbbVie's value is way above its 50-day moving average of $148.14 and way higher than its 200-day moving average of $125.32.Previous days news about AbbVie(ABBV)
- According to Bloomberg Quint on Friday, 8 April, "Drugmakers AbbVie Inc., Pfizer Inc. and Eli Lilly & Co. as well as the largest U.S. health insurer, UnitedHealth Group Inc., all gained more than 6% over the past five days. "